Intervention not reported
Occurrence of angiographic restenosis [ · participants with CHD after PCI
The intervention may leads to lower occurrence of angiographic restenosis [ (low certainty).
1 finding from 1 review
Intervention not reported
Adverse event · participants with CHD after PCI
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Occurence of myocardial infarction [ · participants with CHD after PCI
The intervention may leads to lower occurence of myocardial infarction [ (low certainty).
1 finding from 1 review
Intervention not reported
Occurrence of angina [ · participants with CHD after PCI
It is very uncertain whether the intervention changes occurrence of angina [ (very low certainty).
1 finding from 1 review
Intervention not reported
Occurence of heart failure [ · participants with CHD after PCI
The intervention may leads to lower occurence of heart failure [ (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality [ · participants with CHD after PCI
It is very uncertain whether the intervention changes all‐cause mortality [ (very low certainty).
1 finding from 1 review
Intervention not reported
Mortality due to any cardiovascular event [ · participants with CHD after PCI
It is very uncertain whether the intervention changes mortality due to any cardiovascular event [ (very low certainty).
1 finding from 1 review
Intervention not reported
Use of revascularisation [ · participants with CHD after PCI
The intervention may leads to lower use of revascularisation [ (low certainty).
1 finding from 1 review
Intervention not reported
Cardiovascular event · people with primary prevention of cardiovascular disease in
The intervention showed no clear difference in cardiovascular event (low certainty).
1 finding from 1 review
Intervention not reported
Systolic blood pressure, change from baseline (mmHg) · people with primary prevention of cardiovascular disease in
1 finding from 1 review
Intervention not reported
Diastolic blood pressure, change from baseline (mmHg) · people with primary prevention of cardiovascular disease in
1 finding from 1 review
Intervention not reported
Body mass index, change from baseline (kg/m2) · people with primary prevention of cardiovascular disease in
1 finding from 1 review
Intervention not reported
Waist circumference, change from baseline (cm) · people with primary prevention of cardiovascular disease in
1 finding from 1 review
All‐cause mortality · people with cardiac channelopathies
Implantable cardioverter defibrillators may leads to lower all‐cause mortality compared with β‐blocker therapy (low certainty).
1 finding from 1 review
CVD events: total (fatal and non‐fatal) · people with cardiac channelopathies
Implantable cardioverter defibrillators showed no clear difference in fatal and non‐fatal cardiovascular events compared with β‐blocker therapy (low certainty).
1 finding from 1 review
Adverse events · people with cardiac channelopathies
Implantable cardioverter defibrillators showed no clear difference in adverse events compared with β‐blocker therapy (low certainty).
1 finding from 1 review
Non‐fatal cardiovascular events · people with cardiac channelopathies
Implantable cardioverter defibrillators may leads to higher non‐fatal cardiovascular events compared with β‐blocker therapy (low certainty).
1 finding from 1 review
ICD, inappropriate shock ( · people with cardiac channelopathies
Implantable cardioverter defibrillators may leads to higher inappropriate ICD firing compared with β‐blocker therapy (low certainty).
1 finding from 1 review
Weight (kg) · Adults and children (general population)
1 finding from 1 review
All‐cause mortality · patients with non‐ST elevation acute coronary syndromes
Heparin showed no clear difference in all‐cause mortality compared with placebo (low certainty).
1 finding from 1 review